Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

14
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
14
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

13
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
13
Skin Cancer01:30

Skin Cancer

5.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

23
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
23
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

11
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
11
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

5.1K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset.

Seminars in arthritis and rheumatism·2026
Same author

The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosis.

Rheumatology (Oxford, England)·2026
Same author

Validity and reliability of hand-held dynamometry for proximal strength assessment in systemic sclerosis-associated myopathy.

Seminars in arthritis and rheumatism·2026
Same author

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Arthritis care & research·2026
Same author

Increased Xanthine Oxidoreductase Activity in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

CHEST pulmonary·2026
Same author

Probabilistic Clustering Using Multivariate Growth Mixture Model in Clinical Settings-A Scleroderma Example.

Statistics in medicine·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Related Experiment Video

Updated: Apr 24, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

925

Scleromyxedema.

Laura K Hummers1

  • 1Division of Rheumatology, Department of Medicine, Johns Hopkins Scleroderma Center, Johns Hopkins University, Baltimore, Maryland, USA.

Current Opinion in Rheumatology
|September 13, 2014
PubMed
Summary
This summary is machine-generated.

Scleromyxedema is a rare mucinous deposition disorder. Intravenous immunoglobulin is a successful treatment, though other therapies show promise for this condition that mimics scleroderma.

More Related Videos

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.7K
In Vivo Confocal Microscopy in the Diagnosis and Management of Dry Eye: A Focus on Imaging Protocols and Interpretation
08:13

In Vivo Confocal Microscopy in the Diagnosis and Management of Dry Eye: A Focus on Imaging Protocols and Interpretation

Published on: November 11, 2025

822

Related Experiment Videos

Last Updated: Apr 24, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

925
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.7K
In Vivo Confocal Microscopy in the Diagnosis and Management of Dry Eye: A Focus on Imaging Protocols and Interpretation
08:13

In Vivo Confocal Microscopy in the Diagnosis and Management of Dry Eye: A Focus on Imaging Protocols and Interpretation

Published on: November 11, 2025

822

Area of Science:

  • Dermatology
  • Rheumatology
  • Immunology

Background:

  • Scleromyxedema is a rare mucinous deposition disorder.
  • It shares clinical features with scleroderma, a common mimic.
  • Understanding its pathogenesis and treatment is crucial for patient outcomes.

Purpose of the Study:

  • To synthesize current data on scleromyxedema pathogenesis and treatment.
  • To highlight clinical presentation, systemic features, and outcomes.
  • To differentiate scleromyxedema from scleroderma.

Main Methods:

  • Literature review of recent publications.
  • Analysis of case reports and series on novel therapies.
  • Focus on pathogenesis related to mucin and monoclonal immunoglobulins.

Main Results:

  • Intravenous immunoglobulin (IVIG) is the most successful therapy reported.
  • Other promising treatments include bortezomib, thalidomide, and stem cell transplantation.
  • Pathogenesis is linked to mucin deposition and monoclonal immunoglobulins.

Conclusions:

  • Scleromyxedema is distinct from scleroderma, with unique clinical and organ complications.
  • Patients generally respond well to therapy, with IVIG being a primary treatment.
  • Rare cases report poor outcomes, necessitating continued research.